Trial Profile
An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Tafenoquine (Primary) ; Chloroquine
- Indications Vivax malaria
- Focus Pharmacokinetics
- Acronyms TEACH
- Sponsors GlaxoSmithKline; GSK
- 08 Jan 2021 Results published in the GlaxoSmithKline Media Release
- 08 Jan 2021 According to a GlaxoSmithKline media release, the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the indication of single-dose Kozenis (tafenoquine) to paediatric populations for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children, who are disproportionately affected
- 20 Mar 2020 Status changed from recruiting to completed.